Studies have demonstrated their potential in bladder cancer treatment, as ATOR-1015 BsAb, a human CTLA-4 ˟ OX40 IgG-like BsAb, activates T cells, suppresses regulatory T cells, and reduces tumor growth in bladder cancer models 245. Here, TNFRSF4 is linked to urinary bladder cancer.